Sivan Arber Raviv, Mohammed Alyan, Egor Egorov, Agam Zano, Moshit Yaskin Harush, Calvin Pieters, Hila Korach-Rechtman, Adi Saadya, Galoz Kaneti, Igor Nudelman, Shai Farkash, Ofri Doppelt Flikshtain, Lucy N Mekies, Lilach Koren, Yoav Gal, Ella Dor, Janna Shainsky, Jeny Shklover, Yochai Adir, Avi Schroeder
Acute Respiratory Distress Syndrome (ARDS), associated with Covid-19 infections, is characterized by diffuse lung damage, inflammation and alveolar collapse that impairs gas exchange, leading to hypoxemia and patient' mortality rates above 40%. Here, we describe the development and assessment of 100-nm liposomes that are tailored for pulmonary delivery for treating ARDS, as a model for lung diseases. The liposomal lipid composition (primarily DPPC) was optimized to mimic the lung surfactant composition, and the drug loading process of both methylprednisolone (MPS), a steroid, and N-acetyl cysteine (NAC), a mucolytic agent, reached an encapsulation efficiency of 98% and 92%, respectively...
June 2022: Journal of Controlled Release